Heron Therapeutics Inc. (NASDAQ:HRTX)’s share price fell 9.3% during trading on Thursday . The stock traded as low as $16.42 and last traded at $16.55, with a volume of 379,546 shares changing hands. The stock had previously closed at $18.25.

Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Heron Therapeutics in a report on Monday, May 2nd. They set a “buy” rating and a $41.00 price target on the stock. Noble Financial reaffirmed a “buy” rating and set a $51.00 price target on shares of Heron Therapeutics in a report on Wednesday, April 20th. Jefferies Group reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Thursday, April 28th. Leerink Swann reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, April 19th. Finally, Brean Capital reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Monday, April 18th. One analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $50.30.

The stock has a 50-day moving average price of $17.62 and a 200 day moving average price of $19.07.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.92). On average, equities analysts anticipate that Heron Therapeutics Inc. will post ($3.59) earnings per share for the current year.

Other large investors have recently made changes to their positions in the company. Turner Investments L.P. increased its stake in shares of Heron Therapeutics by 19.7% in the fourth quarter. Turner Investments L.P. now owns 106,080 shares of the biotechnology company’s stock worth $2,832,000 after buying an additional 17,470 shares during the last quarter. Bank of Montreal Can purchased a new stake in shares of Heron Therapeutics during the fourth quarter worth about $3,010,000. GAM Holding AG increased its stake in shares of Heron Therapeutics by 28.9% in the fourth quarter. GAM Holding AG now owns 41,900 shares of the biotechnology company’s stock worth $1,119,000 after buying an additional 9,400 shares during the last quarter. California Public Employees Retirement System increased its stake in shares of Heron Therapeutics by 863.8% in the fourth quarter. California Public Employees Retirement System now owns 90,600 shares of the biotechnology company’s stock worth $2,419,000 after buying an additional 81,200 shares in the last quarter. Finally, Swiss National Bank bought a new stake in shares of Heron Therapeutics during the fourth quarter worth $1,100,000.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.